Table 1 Baseline characteristics of 339 patients who had undergone MWA for HCC
Characteristic | Patients (n = 339) |
|---|---|
Age (years) | 63.2 ± 9.5 |
Sex (Male,%) | 190 (56.1) |
Tumor size (cm) | |
  ≤ 3 cm | 226 (66.7) |
  > 3 cm | 113 (33.3) |
Etiology (%) | |
 HBV | 303 (89.4) |
 HCV | 32 (9.5) |
 NAFLD | 4 (1.1) |
Child–Pugh | |
 A | 309 (91.2) |
 B | 30 (8.8) |
ALBI stage | |
 I | 191 (56.3) |
 II | 148 (43.7) |
AFP (%) | |
  > 200 μg/L | 190 (56.0) |
  ≤ 200 μg/L | 149 (44.0) |
Number of tumors (%) | |
 1 | 292 (86.0) |
  > 1 | 47 (14.0) |
Tumor location (%) | |
 Left lobe | 88 (26) |
 Right lobe | 251 (74) |
 Close to vessel | 92 (27.0) |
 Close to organ/subcapsular | 46 (13.7) |
 Close to the bile duct | 12 (3.5) |
 Nonspecific | 189 (55.8) |
Minimal ablative margin (%) | |
  ≤ 5 mm | 113 (33.3) |
  > 5 mm | 226 (66.7) |
Histological differentiation level (%) | |
 Well-differentiated | 89 (40.5) |
 Moderately differentiated | 107 (48.6) |
 Poorly differentiated | 24 (10.9) |
Tumor type (%) | |
 Primary hepatocellular carcinoma | 93 (27.5) |
 Recurrent hepatocellular carcinoma | 246 (72.5) |
LR-TR category (%) | |
 TR nonviable | 250 (73.7) |
 TR equivocal | 79 (23.3) |
 TR viable | 10 (3.0) |
Follow-up time (months) | 23.21 ± 8.06 |
Median time to LTP or metastasis (months) | 20.95 ± 5.81 |